Close this search box.

Stratpharma AG & Sensus Healthcare Announce Strategic Collaboration for Transformative Superficial Radio Therapy & Post-Treatment Care

October 23, 2017
Collaboration Brings Sensus Healthcare’s SRT Technology and Stratpharma’s Wound Care Medical Devices Together to Advance Radiation Patient Outcomes

SAN DIEGO, Oct. 23, 2017 — Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in post-procedure care in aesthetic dermatology, plastic surgery and radiation oncology, and Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radio Therapy (SRT), announced today a new collaboration that’s focused on advancing the treatment and healing of patients who are affected by skin cancer and keloids on a global scale. The initiative aligns the missions of both companies and encourages the sharing of knowledge and expertise within the industry.

Through various advisory boards, continuing education and industry forums, the companies aim to demonstrate the patient and provider advantages of this first-of-its-kind treatment combination, pairing Sensus Healthcare’s innovative SRT treatment with Stratpharma’s proprietary StrataXRT and Stratamed wound care medical devices. This powerful combination ultimately helps patients to experience less skin reactions and quicker recuperating times post-treatment.

“We are very pleased to be working closely with Sensus Healthcare and its innovative SRT technology, available both in the U.S. and internationally, which represents an entirely new approach in delivering the gold standard in therapy for the treatment of keloids and non-melanoma skin cancers,” said Darren Kerr, Stratpharma AG CEO. “Sensus’ solutions and vision are synergistic with our new wound healing products, Stratamed and StrataXRT, for the management of keloids and radiation dermatitis.”

“As Sensus Healthcare’s mission is to effectively and painlessly treat non-melanoma skin cancer and keloids patients all over the world – while providing a better quality of life for these patients simultaneously – our new collaboration with Stratpharma will ultimately help us to achieve that goal,” added Joe Sardano, Sensus Healthcare CEO. “This collaboration is particularly meaningful, because it aids in the skin healing process overall.”

Stratpharma USA and Sensus Healthcare’s joint effort will commence at the 2017 Dermatologic & Aesthetic Surgery International League (DASIL) Annual Congress, taking place on Oct. 24 through Oct. 28, 2017, in Shanghai, China. As part of the forum, the companies will educate the industry on how their medical devices work synergistically for optimal treatment results.

“As SRT grows in popularity among both doctors and patients, and as more and more people are pursuing non-surgical treatment options for non-melanoma skin cancer and keloids, pairing SRT with Stratapharma’s wound care solutions represents another major advancement in skin treatment today,” concluded Dr. David Goldberg, MD, JD, of Skin Laser & Surgery Specialists of New York and New Jersey and Sensus Healthcare Medical Advisory Board Member.

More information can be found at and

About Stratpharma
Stratpharma Inc. USA is a U.S. subsidiary of Stratpharma AG, the Swiss company based in Basel that specializes in innovative film-forming full-contact topical medical products to improve medical and aesthetic outcomes in post-procedure care in aesthetic dermatology, plastic surgery, and radiation oncology. Headquartered in San Diego, California, Stratpharma Inc. USA is responsible for bringing product distribution and education to U.S. healthcare professionals and patients. In addition to the U.S., Stratpharma products are registered in more than 70 countries and sold in over 50 countries all over the world. For more information, visit

About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

Media Contact for Stratpharma AG
GG Benitez
GG Benitez & Assoc. PR
[email protected]

Media Contacts for Sensus Healthcare
Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
212-896-1241 / 212-896-1206
[email protected] / [email protected]

View original content:–sensus-healthcare-announce-strategic-collaboration-for-transformative-superficial-radiation-therapy–post-treatment-care-300540873.html

SOURCE Sensus Healthcare